doi:10.1056/nejmoa2500969 17.Yellow Card: dulaglutide
Receive dedicated guidance and support from a clinician throughout your weight loss journey
doi: 10.3389/fendo.2025.1683419 Received 12 August 2025 Revised 04 December 2025 Accepted 30 December 2025 Published 23 January 2026 Volume 16 - 2025 Edited by Claudia Lagranha, Federal University of Pernambuco, Brazil Reviewed by Lei Zhao, China Medical University, China Michihiro Takahashi, Takahashi Psychiatric Clinic, Japan Sundararajan Mahalingam, University of Nebraska Omaha, United States Rodolfo Nunes, Federal University of Ceara, Brazil Updates Copyright 2026 Doval-Caballero, Ferreira-Hermosillo, Eugenio-Ponce, Garca-Senz, Ibarra-Salce, Tenorio-Rojo, Luna-Avila, Gete-Palacios, Prez-Hernndez, Rojas-Miln, Lpez-Cruz and Mndez-Hernndez
9:e0101323
Clinical Scenarios: When Each Model May Be Appropriate Ro's rapid-access model suits patients with straightforward health profiles, no contraindications, and confirmed GLP-1 tolerance or prior use